Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid

Primary tabs

field_vote: 
Average: 5.5 (2 votes)
Number of included patients: 
References: 
Therapeutic intervention: 
Disease(s): 
Therapeutic Substance(s): 

Drugs Exp Clin Res. 1992;18 Suppl:63-7.

Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid
alkaloid derivatives from Chelidonium majus L. (Ukrain).

Staniszewski A, Slesak B, Ko?odziej J, Har?ozi?ska-Szmyrka A, Nowicky JW.

Department of Thoracic Surgery, Wroc?aw Medical School, Poland.

Lymphocyte subsets were evaluated in nine men (aged 42-68 years, mean 57 years)
with histologically proven lung cancer, previously untreated. Lymphocyte
subpopulations were quantified by immunofluorescence using monoclonal antibodies
against total T-cells, T-helper and T-suppressor cells. In addition, the
percentage of NK cells and the helper/suppressor (H/S) ratio were evaluated. The
number of B-cells was determined by surface immunoglobulin immunofluorescence.
Chelidonium majus L. (preparation Ukrain) was applied as an intravenous injection
every three days. One course consisted of 10 applications of 10 mg each. All
immunological tests were performed before and after drug administration. The
treatment was generally well tolerated. The results showed an increase in the
proportion of total T-cells, and a significant decrease in the percentage of
T-suppressor cells. The normalization of the H/S ratio was also noted. However,
there were no signs of activation of NK, T-helper and B-cells. The restoration of
cellular immunity was accompanied by an improvement in the clinical course of the
disease. This effect was particularly pronounced in patients who responded to
further chemotherapy. Objective tumour regression (CR+PR) was seen in 44.4% of
treated patients. Four out of nine patients (44.4%) died of progressive disease
during the course of this study. It is concluded that Ukrain can be
immunologically effective in lung cancer patients and can improve human cellular
response.

PMID: 1305047